Related Experiment Video
Updated: Aug 21, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine
Eduardo Shahar1, Norberto Krivoy, Sara Weltfriend
1Institute of Allergy, Clinical Immunology and AIDS, Rambam Medical Center, 31096 Haifa, Israel. ed_shahar@rambam.health.gov.il
Abstract:
Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis. However, its use has recently been limited because of adverse cutaneous and hepatic effects. We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.
Related Concept Videos
Cryptococcal Meningitis
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacokinetics in Pediatric Patients: Drug Excretion
Inhibitors of Viral Protein Synthesis

